Connor, Clark & Lunn Investment Management Ltd. Supernus Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 214,864 shares of SUPN stock, worth $8.06 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
214,864
Previous 87,444
145.72%
Holding current value
$8.06 Million
Previous $2.34 Million
186.4%
% of portfolio
0.04%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding SUPN
# of Institutions
279Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$390 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$230 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$191 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$108 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$98.7 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.01B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...